All In Biotech

Drug Trial Radar · NCT07374471

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Jul 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Mage BiologicsIndustry
Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if MB-001, an oral biologic, is able to treat patients with ulcerative colitis. Participants will be asked to take MB-001 or a matching placebo once-daily for a period of 12 weeks. Researchers will compare MB-001 to placebo to investigate its effects on clinical symptoms as well as endoscopic and histopathological findings. Patients will be offered open-label extension for another 12 weeks following the double-blind, placebo-controlled part of the study. Participants will keep a daily diary to record their symptoms and will have up to nine clinic visits.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • MB-001Biological

    oral capsule formulation

  • Matching placebo to MB-001Biological

    oral capsule formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: From study start until 4 weeks after end of treatment
  2. Changes in laboratory parameters: Platelet countTime frame: Week 12
  3. Changes in laboratory parameter: HemoglobinTime frame: Week 12
  4. Changes in laboratory parameter: HematocritTime frame: Week 12
  5. Changes in laboratory parameter: Red Blood Cell (RBC) countTime frame: Week 12
  6. Changes in laboratory parameter: Prothrombin timeTime frame: Week 12
  7. Number of participants with abnormal laboratory tests resultsTime frame: Week 12
  8. Number of participants with abnormal urinalysis resultsTime frame: Week 12
  9. Proportion of participants achieving clinical remissionTime frame: Week 12

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • 2001

    Tbilisi, Georgia · Recruiting

  • 3001

    Chisinau, Moldova · Recruiting

  • 4002

    Katowice, Poland · Recruiting

  • 4001

    Warsaw, Poland · Recruiting

  • 4003

    Wroclaw, Poland · Recruiting

  • 1003

    Ivano-Frankivsk, Ukraine · Recruiting

  • 1001

    Kyiv, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.